Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/222687
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

AuthorsGarcía-Sanz, Ramón; Dogliotti, Irene; Zaccaria, Gian Maria; Ocio, Enrique M. CSIC ORCID ; Rubio, Araceli; Murillo, Ilda; Escalante, Fernando; Aguilera, Carmen; García-Mateo, Aránzazu; García de Coca, Alfonso; Hernández, Roberto; Dávila, Julio; Puig, Noemi; García-Alvarez, María; Chillón, M. del Carmen; Alcoceba, Miguel; Medina, Alejandro; González-Calle, Verónica; Sarasquete, María Eugenia; González, Marcos CSIC ORCID ; Gutiérrez, Norma Carmen; Jiménez, Cristina CSIC
Issue DateMar-2021
PublisherJohn Wiley & Sons
CitationBritish Journal of Haematology 192(5): 843-852 (2020)
AbstractDeletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients. Its effect on patient outcome has not been completely established. We used fluorescence in situ hybridisation to analyse the prevalence of del6q in selected CD19+ bone marrow cells of 225 patients with newly diagnosed immunoglobulin M (IgM) monoclonal gammopathies. Del6q was identified in one of 27 (4%) cases of IgM‐monoclonal gammopathy of undetermined significance, nine of 105 (9%) of asymptomatic WM (aWM), and 28/93 (30%) of symptomatic WM (sWM), and was associated with adverse prognostic features and higher International Prognostic Scoring System for WM (IPSSWM) score. Asymptomatic patients with del6q ultimately required therapy more often and had a shorter time to transformation (TT) to symptomatic disease (median TT, 30 months vs. 199 months, respectively, P < 0·001). When treatment was required, 6q‐deleted patients had shorter progression‐free survival (median 20 vs. 47 months, P < 0·001). The presence of del6q translated into shorter overall survival (OS), irrespective of the initial diagnosis, with a median OS of 90 compared with 131 months in non‐del6q patients (P = 0·01). In summary, our study shows that del6q in IgM gammopathy is associated with symptomatic disease, need for treatment and poorer clinical outcomes.
Publisher version (URL)https://doi.org/10.1111/bjh.17028
URIhttp://hdl.handle.net/10261/222687
DOI10.1111/bjh.17028
ISSN0007-1048
E-ISSN1365-214
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

SCOPUSTM   
Citations

8
checked on May 13, 2022

WEB OF SCIENCETM
Citations

7
checked on May 16, 2022

Page view(s)

112
checked on May 16, 2022

Download(s)

24
checked on May 16, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.